- Home
- TCRX vs TNYA Comparison
TCRX vs TNYA Comparison
Compare TCRX & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- TNYA
- Stock Information
- Founded
- TCRX 2018
- TNYA 2016
- Country
- TCRX United States
- TNYA United States
- Employees
- TCRX N/A
- TNYA N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- TCRX Health Care
- TNYA Health Care
- Exchange
- TCRX Nasdaq
- TNYA Nasdaq
- Market Cap
- TCRX 90.5M
- TNYA 74.5M
- IPO Year
- TCRX 2021
- TNYA 2021
- Fundamental
- Price
- TCRX $1.38
- TNYA $0.44
- Analyst Decision
- TCRX Strong Buy
- TNYA Strong Buy
- Analyst Count
- TCRX 7
- TNYA 6
- Target Price
- TCRX $9.86
- TNYA $8.60
- AVG Volume (30 Days)
- TCRX 396.8K
- TNYA 1.8M
- Earning Date
- TCRX 05-06-2025
- TNYA 05-07-2025
- Dividend Yield
- TCRX N/A
- TNYA N/A
- EPS Growth
- TCRX N/A
- TNYA N/A
- EPS
- TCRX N/A
- TNYA N/A
- Revenue
- TCRX $4,421,000.00
- TNYA N/A
- Revenue This Year
- TCRX $47.30
- TNYA N/A
- Revenue Next Year
- TCRX $74.30
- TNYA N/A
- P/E Ratio
- TCRX N/A
- TNYA N/A
- Revenue Growth
- TCRX N/A
- TNYA N/A
- 52 Week Low
- TCRX $1.02
- TNYA $0.39
- 52 Week High
- TCRX $9.69
- TNYA $4.78
- Technical
- Relative Strength Index (RSI)
- TCRX 42.86
- TNYA 37.91
- Support Level
- TCRX $1.32
- TNYA $0.45
- Resistance Level
- TCRX $1.65
- TNYA $0.53
- Average True Range (ATR)
- TCRX 0.13
- TNYA 0.04
- MACD
- TCRX -0.01
- TNYA 0.01
- Stochastic Oscillator
- TCRX 14.63
- TNYA 18.23
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.